title: Proteomic approach to the study of statin pleiotropy in kidney transplant patients.
abstract: OBJECTIVE
  Statins are prescribed in kidney transplant recipients in order to manage dyslipidemia, a common complication in these patients. The efficacy of statins in reducing cholesterol levels has been accompanied by pleiotropic effects. Fifty-four kidney transplant patients were included in the present study, the objective of which was to ascertain the effect of 12 weeks of atorvastatin therapy (10 mg/day) on the patients' lipid profile, renal function, markers of inflammation and plasma peptide profile.
  
  
  METHODS
  Biochemical variables were determined with a routine clinical laboratory analyzer, and the proteomic approach was based on magnetic particle-assisted sample processing coupled to mass spectrometry readout.
  
  
  RESULTS
  Atorvastatin therapy improved the lipid profile of patients and caused significant changes in their plasma peptide profile; peptides with m/z 1063 and 1898 decreased after treatment and were identified as fragments derived from molecules involved in vascular inflammation, i.e. high-molecular-weight kininogen and complement factor C4, respectively.
  
  
  CONCLUSIONS
  These findings may contribute to the growing body of evidence of the anti-inflammatory actions attributed to statins, by which these drugs could improve these patients' clinical status.
authors.affiliation: Department of Nephrology, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Pérez
authors.forename: Maribel
authors.initials: M
authors.lastname: Navarro-Muñoz
authors.forename: Sebastián
authors.initials: S
authors.lastname: Mas
authors.forename: Beatriz
authors.initials: B
authors.lastname: Bayés
authors.forename: Mari Cruz
authors.initials: MC
authors.lastname: Pastor
authors.forename: Eva
authors.initials: E
authors.lastname: Martínez-Cáceres
authors.forename: Ricardo
authors.initials: R
authors.lastname: Lauzurica
authors.forename: Jesús
authors.initials: J
authors.lastname: Egido
authors.forename: Ramón
authors.initials: R
authors.lastname: Romero
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007124:Immunoenzyme Techniques; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D010446:Peptide Fragments / Q000097:blood*; D011446:Prospective Studies; D040901:Proteomics / Q000379:methods*; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D008055:Lipids; D010446:Peptide Fragments; D011758:Pyrroles; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000069059:Atorvastatin